The company
Lexeo Therapeutics, Inc.
LXEO · Nasdaq
LXEO stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 37 weeks. It is 45.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 37
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $1.5M
- Officials’ trades on record
- 0
- Institutions holding
- 140 (+6)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Richard Nolan TownsendChief Executive Officer | sold | 3,345at $4.95 | 18 Aug 2026filed 19 Aug 2026 |
| Jose Manuel OteroChief Operating Officer | sold | 1,304at $4.96 | 18 Aug 2026filed 19 Aug 2026 |
| Louis Edward TamayoChief Financial Officer | sold | 4,117at $4.91 | 18 Aug 2026filed 19 Aug 2026 |
| Richard Nolan TownsendChief Executive Officer | sold | 25,947at $4.48 | 1 Jul 2026filed 1 Jul 2026 |
| Jose Manuel OteroChief Operating Officer | sold | 4,666at $4.48 | 1 Jul 2026filed 1 Jul 2026 |
| Louis Edward TamayoChief Financial Officer | sold | 4,641at $4.49 | 1 Jul 2026filed 1 Jul 2026 |
| Narinder Pal BhallaChief Medical Officer | sold | 22,306at $4.42 | 1 Jul 2026filed 1 Jul 2026 |
| Richard Nolan TownsendChief Executive Officer | sold | 3,342at $5.06 | 18 May 2026filed 20 May 2026 |
| Jose Manuel OteroChief Operating Officer | sold | 1,302at $5.07 | 18 May 2026filed 20 May 2026 |
| Richard Nolan TownsendChief Executive Officer | sold | 55,000at $5.69 | 6 Apr 2026filed 7 Apr 2026 |
| Richard Nolan TownsendChief Executive Officer | sold | 10,173at $6.38 | 18 Feb 2026filed 20 Feb 2026 |
| Jose Manuel OteroChief Operating Officer | sold | 3,016at $6.40 | 18 Feb 2026filed 20 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| MONTANOVA CAPITAL, LLCadded · filed 14 Aug 2026 | 6,384,200$29.7M | +5,134,200+410.7% |
| Affinity Asset Advisors, LLCadded · filed 13 Aug 2026 | 5,807,611$27.0M | +757,400+15.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 5,739,455$26.7M | +628,584+12.3% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 5,000,000$23.3M | 00.0% |
| Frazier Life Sciences Management, L.P.added · filed 14 Aug 2026 | 4,824,725$22.5M | +400,000+9.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,354,757$20.3M | +786,515+22.0% |
| Vestal Point Capital, LPreduced · filed 14 Aug 2026 | 4,320,000$20.1M | -155,000−3.5% |
| Paradigm Biocapital Advisors LPreduced · filed 14 Aug 2026 | 4,175,382$19.4M | -2,008,752−32.5% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 3,954,691$18.4M | +3,954,691 |
| ORBIMED ADVISORS LLCadded · filed 14 Aug 2026 | 3,947,850$18.4M | +345,400+9.6% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.